|
Real-time Estimate
Cboe Europe
11:09:34 2026-10-12 EDT
|
5-day change | 1st Jan Change | ||
| 1,763.75 GBX | +0.79% |
|
+0.23% | -3.37% |
| 10-09 | Pennsylvania says GSK to invest more than $800 million in biopharma hub, create 300 jobs | RE |
| 10-09 | Chai Discovery and GSK Announce Collaboration Following Successful Wet-Lab Evaluation | CI |
Company Valuation: GSK plc
Data adjusted to current consolidation scope
| Fiscal Period: December | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 | 2027 | 2028 |
|---|---|---|---|---|---|---|---|---|
| Market Cap 1 | 80,458 | 58,381 | 59,112 | 54,944 | 73,201 | 70,123 | - | - |
| Change | - | -27.44% | 1.25% | -7.05% | 33.23% | -4.21% | - | - |
| Enterprise Value (EV) 1 | 100,296 | 75,578 | 74,152 | 68,039 | 87,654 | 91,333 | 88,613 | 85,777 |
| Change | - | -24.65% | -1.89% | -8.24% | 28.83% | 4.2% | -2.98% | -3.2% |
| P/E | 18.6x | 3.93x | 11.9x | 21.3x | 12.9x | 13.6x | 11.2x | 10.3x |
| PBR | 5.34x | 5.47x | 4.4x | 4.02x | 4.51x | 4.38x | 3.85x | 3.4x |
| PEG | - | 0x | -0.2x | -0.4x | 0x | -1.56x | 0.5x | 1.26x |
| Capitalization / Revenue | 2.36x | 1.99x | 1.95x | 1.75x | 2.24x | 2.07x | 1.98x | 1.92x |
| EV / Revenue | 2.94x | 2.58x | 2.45x | 2.17x | 2.68x | 2.69x | 2.5x | 2.34x |
| EV / EBITDA | 8.85x | 7.23x | 6.37x | 6.36x | 7.77x | 7.85x | 7.11x | 6.66x |
| EV / EBIT | 11.4x | 9.27x | 8.44x | 7.44x | 8.96x | 8.84x | 8x | 7.45x |
| EV / FCF | 22.6x | 12.1x | 13.6x | 13x | 13.7x | 16.3x | 15.5x | 12.8x |
| FCF Yield | 4.42% | 8.28% | 7.36% | 7.67% | 7.32% | 6.14% | 6.46% | 7.78% |
| Dividend per Share 2 | 1 | 0.6125 | 0.58 | 0.61 | 0.66 | 0.6945 | 0.7481 | 0.7829 |
| Rate of return | 4.98% | 4.26% | 4% | 4.53% | 3.62% | 3.97% | 4.27% | 4.47% |
| EPS 2 | 1.082 | 3.662 | 1.216 | 0.632 | 1.411 | 1.288 | 1.566 | 1.693 |
| Distribution rate | 92.4% | 16.7% | 47.7% | 96.5% | 46.8% | 53.9% | 47.8% | 46.2% |
| Net sales 1 | 34,114 | 29,324 | 30,328 | 31,376 | 32,667 | 33,918 | 35,505 | 36,609 |
| EBITDA 1 | 11,330 | 10,449 | 11,635 | 10,693 | 11,278 | 11,638 | 12,467 | 12,871 |
| EBIT 1 | 8,806 | 8,151 | 8,786 | 9,148 | 9,783 | 10,327 | 11,077 | 11,516 |
| Net income 1 | 4,385 | 14,956 | 4,928 | 2,575 | 5,716 | 5,191 | 6,216 | 6,758 |
| Net Debt 1 | 19,838 | 17,197 | 15,040 | 13,095 | 14,453 | 21,210 | 18,490 | 15,654 |
| Reference price 2 | 20.08 | 14.38 | 14.50 | 13.46 | 18.24 | 17.50 | 17.50 | 17.50 |
| Nbr of stocks (in thousands) | 4,006,383 | 4,060,999 | 4,076,145 | 4,080,519 | 4,012,126 | 4,007,011 | - | - |
| Announcement Date | 2/9/22 | 2/1/23 | 1/31/24 | 2/5/25 | 2/4/26 | - | - | - |
1GBP in Million2GBP
Estimates
P/E, Detailed evolution
| P/E (Y) | EV / Sales (Y) | EV / EBITDA (Y) | Dividend Yield (Y) | Capi.($) | ||
|---|---|---|---|---|---|---|
 | 13.59x | 2.69x | 7.85x | 3.97% | 92.79B | |
| 33.55x | 12.18x | 25.21x | 0.58% | 1,051B | |
| 29x | 6.42x | 18.31x | 2.04% | 630B | |
| 35.19x | 8.13x | 16.76x | 2.51% | 489B | |
| 111.24x | 5.93x | 25.27x | 2.34% | 359B | |
| 19.31x | 4.72x | 11.72x | 2.8% | 344B | |
| 20.06x | 5.27x | 12.98x | 3.02% | 272B | |
| 20.56x | 4.21x | 12.07x | 2.1% | 246B | |
| 26.34x | 6.83x | 12.21x | 2.43% | 224B | |
| -45.84x | 6.75x | 26.31x | 2.18% | 187B | |
| Average | 26.30x | 6.31x | 16.87x | 2.4% | 389.65B | |
| Weighted average by Cap. | 32.45x | 7.72x | 19.05x | 1.95% |
Y-o-Y evolution of P/E
Historical PBR trend
Evolution Enterprise Value / Sales
Change in Enterprise Value/EBITDA
Year-on-year evolution of the Yield
- Stock Market
- Stocks
- GSK Stock
- Valuation GSK plc
Select your edition
All financial news and data tailored to specific country editions
